Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Acurx Pharmaceuticals, Inc. (ACXP : NSDQ)

• Company Description    Acurx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. It focused on developing new antibiotics to treat infections. Acurx Pharmaceuticals Inc. is based in STATEN ISLAND, N.Y. Number of Employees: 3

• Price / Volume Information    Yesterday's Closing Price: $2.70 Daily Weekly Monthly 20 Day Moving Average: 15,861 shares Shares Outstanding: 10.26 (millions) Market Capitalization: $27.71 (millions) Beta: 52 Week High: $8.74 52 Week Low: $2.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -28.76% -21.94% 12 Week -34.15% -28.55% Year To Date -37.52% -25.70%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 259 LIBERTY AVENUE - STATEN ISLAND,NY 10305 USA ph: 917-533-1469 fax: - davidluci@acurxpharma.com http://www.acurxpharma.com

• General Corporate Information    Officers David P. Luci - Chief Executive Officer and President Robert J. DeLuccia - Executive Chairman Robert G. Shawah - Chief Financial Officer Carl V. Sailer - Director Joseph C. Scodari - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00510M104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/15/22 Share - Related Items Shares Outstanding: 10.26 Most Recent Split Date: (:1) Beta: Market Capitalization: $27.71 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/15/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.59 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -13.04% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -105.43 12/31/21 - -114.12 09/30/21 - -128.25 ROA 03/31/22 - -97.83 12/31/21 - -104.77 09/30/21 - -116.09 Current Ratio 03/31/22 - 17.89 12/31/21 - 15.70 09/30/21 - 21.05 Quick Ratio 03/31/22 - 17.89 12/31/21 - 15.70 09/30/21 - 21.05 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 1.04 12/31/21 - 1.23 09/30/21 - 1.41 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©